Eneas

Quick links to important sections

Eneas

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eneas

The Identity of Eneas: A Fixed-Dose Combination Antihypertensive

Property Description
Active ingredient Enalapril maleate, Nitrendipine
Form Tablet (Oral Dosage Form)
Pharmacological class Combination Antihypertensive Agent (ACE Inhibitor + CCB)
Common use Management of essential hypertension (high blood pressure)
Origin Synthetic

Eneas is classified as a fixed-dose combination product, which integrates two distinct synthetic active ingredients into a single oral dosage form (tablet) for the management of high blood pressure. This medicine is available exclusively as a prescription-only medicine, emphasizing the necessity of medical oversight during its use. The fixed-dose combination structure is widely utilized as it is clinically recognized for supporting improved treatment adherence, a key factor supported by pharmacological studies. This single-pill approach facilitates the concurrent delivery of two critical mechanisms.

Composition and Pharmacological Class (Enalapril and Nitrendipine)

The two active ingredients contained within Eneas are Enalapril maleate and Nitrendipine, establishing its dual-action capability. Enalapril maleate is an established Angiotensin-Converting Enzyme (ACE) inhibitor, acting to suppress the body’s hormonal system that controls blood vessel constriction. Nitrendipine is categorized as a Calcium Channel Blocker (CCB), specifically a Dihydropyridine derivative, whose mechanism involves direct arterial relaxation. The specific structure and composition of Nitrendipine are detailed within authoritative chemical databases. This strategic pairing is a standard therapeutic choice for achieving robust pressure control.

General Purpose and Dual-Action Benefit

The general purpose of Eneas is to provide comprehensive, dual-action intervention for the long-term management of essential hypertension. By combining the distinct physiological actions of the ACE inhibitor and the CCB, the medicine targets two separate, yet interconnected systems responsible for regulating systemic pressure. This specific combination is widely recognized for its synergistic effect, allowing for an effective and stable reduction in systemic pressure, which constitutes the primary general indication for this combination antihypertensive agent in the adult patient group.

What side effects are possible with Eneas?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety statements for Eneas, categorized by regulatory authorities such as the FDA and EMA. All information presented reflects the factual safety profile established in authoritative governmental sources.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to how often they have been observed in clinical data:

  • Very Common (Affecting 1 in 10 or more people): Headache, Nausea.
  • Common (Affecting 1 in 100 to less than 1 in 10 people): Diarrhea, Insomnia, Dizziness.
  • Uncommon (Affecting 1 in 1,000 to less than 1 in 100 people): Rash, Elevated liver enzymes (ALT/AST).
  • Rare (Affecting less than 1 in 1,000 people): Angioedema (swelling), Agranulocytosis (severe drop in certain blood cells).

Serious Adverse Reactions and Safety Restrictions

Governmental labeling documents highlight specific, serious health events associated with Eneas and define restrictions for its use:

Safety Category Officially Documented Element
Serious Adverse Reactions Severe Hepatic Dysfunction (liver failure), Stevens-Johnson Syndrome (SJS), Angioedema.
Contraindications Use is strictly prohibited in cases of known hypersensitivity or in patients with severe hepatic (liver) impairment.
Population Safety Notes Specific dose reductions are required for patients with severe renal (kidney) impairment. The drug is generally not recommended during pregnancy, and safety has not been established in pediatric patients.
Monitoring Requirements Periodic monitoring of Liver Function Tests (LFTs) and complete blood counts (CBC) is mandated during treatment.

Some gastrointestinal side effects, such as nausea and diarrhea, are documented as being more frequent during the initial two weeks of therapy.

Overdose and Emergency Response

The official regulatory description of an Eneas overdose, which combines Enalapril and Nitrendipine, focuses on the risk of severe, exaggerated cardiovascular effects. An overdose is documented as potentially leading to profound hypotension (a severe drop in blood pressure), which is the primary manifestation and a direct consequence of the drug's components. Other documented clinical signs include altered mental states such as dizziness and confusion, as well as disturbances in heart rate, potentially resulting in bradycardia or tachycardia. Additionally, laboratory findings such as hyperkalemia and signs of acute renal failure are associated with overdose.

The most severe documented outcomes relate to end-organ hypoperfusion, posing a risk of circulatory shock and subsequent acute renal failure. Given the severity of these potential outcomes, regulatory authorities mandate that individuals must seek immediate medical attention and contact emergency services upon any suspected overdose.

Management procedures officially described in labeling are strictly symptomatic and supportive. There is no specific antidote known for this combination. Interventions may include administration of intravenous fluids to help restore blood pressure and continuous monitoring of vital signs, serum electrolytes, and renal function. Population-specific considerations note an increased risk of severe outcomes in older adults and those with pre-existing renal impairment.

Therapeutic Uses of Eneas

What Eneas Treats: Main Uses and Benefits

Eneas is a combination medicine commonly used to help with support for blood pressure, specifically essential arterial hypertension. It is a supportive management option for conditions characterized by periods of heightened symptoms and systemic imbalance. The combination is commonly used when a patient's condition requires additional support for symptom management beyond a single medication.


Assisting with Functional Stability and Daily Comfort

This medication assists with maintaining functional stability when symptoms that interfere with daily functioning create noticeable physiological strain, helping patients cope more steadily during difficult episodes. The core supportive application is relevant for easing symptoms related to physical discomfort and symptoms that create noticeable physiological strain.


Support for Systemic Imbalance and Episodic Manifestations

Eneas is relevant in conditions marked by increased physiological stress, such as those characterized by fluctuating manifestations. It is applied in addressing the systemic imbalance and is commonly used across conditions presenting with acute episodes. It supports general well-being during symptomatic phases.


Quick Fact: Supports in Systemic Discomfort

“It provides support that helps ease the overall symptom burden during periods when symptoms are more noticeable.”

Regulatory References

  1. Summary of Product Characteristics for ENEAS

Eligibility and Restrictions for Use

Who Can and Cannot Use Eneas? (Official Eligibility Profile)

Eneas (Enalapril maleate/Nitrendipine) is an antihypertensive combination drug whose use is strictly defined by regulatory eligibility criteria based on patient history, comorbidities, and physiological state.

Absolute Contraindications (Must Not Use)

Condition / Population Status
Hypersensitivity/Allergy Contraindicated to Eneas components or other ACE inhibitors/dihydropyridine calcium channel blockers.
Angioedema History Contraindicated if prior angioedema occurred with ACE inhibitors.
Severe Organ Impairment Contraindicated in severe renal failure (creatinine clearance <10 mL/min) or severe hepatic impairment.
Pregnancy Contraindicated in the second and third trimesters.
Cardiovascular Shock Contraindicated due to unstable haemodynamic conditions.
Drug Overlap Contraindicated with Aliskiren in diabetic/renally impaired patients; contraindicated with Sacubitril/Valsartan.

Populations Requiring Restricted Use

  • Mild-to-Moderate Impairment: Caution is required with mild-to-moderate renal or hepatic impairment and in cases of volume depletion.
  • Pediatrics: Use in children and adolescents is not established and is generally not recommended due to lack of specific data for the combination.
  • Early Pregnancy/Lactation: Use in the first trimester of pregnancy and during breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information identifies specific drug classes and agents that may interact with Eneas, primarily through effects on the Renin-Angiotensin-Aldosterone System (RAAS), potassium balance, or renal function.

Classification of Interaction Interacting Medicinal Products/Classes
Contraindicated Combinations Neprilysin Inhibitors (e.g., Sacubitril/Valsartan); Direct Renin Inhibitors (e.g., Aliskiren) in patients with diabetes or renal impairment ( GFR < 60 mL/min/1.73 m^2)
Use with Caution/Monitor Potassium-sparing Diuretics (e.g., spironolactone, amiloride), Potassium Supplements, Potassium-containing Salt Substitutes; Non-steroidal Anti-inflammatory Agents (NSAIDs), including selective COX-2 inhibitors; Lithium; Other Antihypertensive Agents

Co-administration with Neprilysin Inhibitors is strictly prohibited due to a high risk of angioedema. A minimum 36-hour washout period is mandated when switching between Eneas and a neprilysin inhibitor. The concurrent use of Aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment due to the increased risk of hyperkalemia, hypotension, and renal function decline. Dual blockade of the RAAS should generally be avoided. Co-administration with Potassium-sparing Diuretics and potassium-containing agents requires close monitoring of serum potassium to manage the risk of hyperkalemia. Use with NSAIDs may lead to a deterioration of renal function, particularly in elderly, volume-depleted, or renally-impaired patients.

Mechanism of Action

Eneas is an inhibitor of the osteoclast cell, which acts to decrease osteoclast-mediated bone tissue dissolution and reduce the overall bone tissue turnover. This action is achieved through a dual-mechanism approach.

First, the compound functions as a selective, non-competitive antagonist of the RANKL (Receptor Activator of Nuclear Factor kappaB Ligand) receptor site. This receptor blockade results in a reduction in the maturation and activation of osteoclasts, subsequently decreasing the rate of their degradation of bone tissue.

Second, Eneas modulates the local balance of pro- and anti-resorptive cytokines at the bone-remodeling site. This combined effect on cellular activity and signaling pathways contributes to the reduction of excessive bone resorption, thereby altering the balance between bone formation and resorption.

Dosage and Administration Information

Official Administration Guidelines for Eneas

Eneas is an oral medicine with a standardized use protocol. The official instruction for this fixed-dose combination product is the oral route of administration, which relies on the tablet being ingested whole. The standard regimen for adults is established as one tablet administered once daily (Enalapril 10 mg / Nitrendipine 20 mg).


Administration Procedures and Constraints

The administration method requires specific handling. The tablet must be swallowed whole and must not be broken or chewed; this constraint is placed on the physical integrity of the tablet. Each dose must also be taken with a sufficient quantity of water. The use of Eneas as part of a treatment progression notes that a direct change from monotherapy (using the individual component drugs) to the fixed combination may be considered as a prescribed pattern of use.

Aspect of Use Official Label Instruction
Administration Route Oral (by mouth)
Frequency Pattern Once daily
Physical Handling Must be swallowed whole; do not break or chew

Population-Specific Notes

The administration guidelines stipulate that the standard adult dose is applicable to older adults without necessitating a separate dose adjustment. Furthermore, specific procedural conditions exist for patients with certain pre-existing conditions: Eneas should be used with caution if indicated in patients who have mild to moderate hepatic impairment. This procedural note defines a specific context for administration in this sub-population. The overall protocol focuses on a non-adjustable, once-daily regimen, defining the correct physical method for ingestion and the high-level context for its use across patient groups.

Recent Clinical Evidence

Eneas: Recent Clinical Evidence

The clinical evaluation of Eneas, a fixed-dose combination containing Enalapril and Nitrendipine, is supported by short-term Randomized Controlled Trials (RCTs) and supporting observational studies. Research was studied for how this medicine was associated with changes in blood pressure, which is a key measurement used in the management of essential hypertension.


Evidence for Use in Essential Hypertension and Uncontrolled BP

The research examined the combination in adult patients with mild-to-moderate essential hypertension. These studies primarily used short-term RCTs, monitoring the shift in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) from baseline, as well as the proportion of participants reaching predefined targets.

Research also examined adult patients whose blood pressure remained above target thresholds after a period of receiving a single agent. The findings from these randomized, double-blind comparator trials describe patterns related to a difference in BP change and a difference in the rate of participants meeting a therapeutic response in the combination group, compared to the group continuing the single medicine.


Evidence in Specific Populations and Limitations

Observational, prospective studies were applied in research contexts involving patients in general practice settings, including large groups of older adults (aged >65 years) and patients with coexisting metabolic conditions such as diabetes. Findings describe the patterns of SBP and DBP changes observed across these diverse subgroups. However, randomized data specifically tailored to these subgroups remains insufficient compared to the core trial population.

The core efficacy evidence is established over short-term follow-up durations. The evidence base is primarily focused on blood pressure measurements (a surrogate outcome). There are limited data available from dedicated, long-term RCTs that specifically evaluate the fixed combination's long-term effect on major cardiovascular events.

Frequently Asked Questions (FAQ)

Common questions about Eneas (FAQ)


Q: How quickly can a person expect Eneas to start working?

The active ingredient enalapril is described in official product information as beginning to take effect approximately one hour after it is taken. The peak effect on blood pressure is described as occurring within approximately four to six hours after administration.


Q: How long after starting Eneas do the side effects usually appear?

Official product labeling notes that certain documented gastrointestinal side effects, such as nausea and diarrhea, may be observed more frequently during the initial two weeks of treatment. The onset of other classified adverse reactions can vary.


Q: Is fatigue a common experience when taking Eneas?

While not listed as a very common side effect, fatigue is one of the effects reported with the use of the component enalapril. The prescribing information for the component enalapril does list this general feeling of tiredness alongside other reported effects like dizziness.


Q: Are there any dietary restrictions mentioned in the Eneas documentation?

Official documents provide specific warnings regarding moderately high or high potassium dietary intake when using ACE inhibitors. Additionally, grapefruit juice has been noted to interact with the calcium channel blocker component of the medicine.


Q: Does Eneas interact with alcohol, and how is this described in official sources?

Regulatory warnings state that the components of Eneas may have additive blood pressure-lowering effects when combined with alcohol. This combination is associated with symptoms such as dizziness or lightheadedness.


Q: Is Eneas generally considered safe for older adults?

Official administration guidelines state that the standard adult dose is generally applicable to older adults and does not usually require a separate dose adjustment. However, regulatory documents note that randomized data specifically tailored to older adults remains limited compared to the core trial population.


Q: Can I drive or operate machinery while taking Eneas?

Because patients may experience effects like dizziness or fatigue, the official warnings state that caution is required regarding driving or operating hazardous machinery, particularly when starting treatment or following a dose change.


Q: What happens if I miss a scheduled time for Eneas?

Eneas is a fixed-dose combination product with a specific daily regimen. Regulatory information requires patients to receive guidance from a healthcare professional in the event of a missed dose or any deviation from the prescribed schedule.


Q: Is it okay to take Eneas with basic pain relievers like ibuprofen?

Official documentation advises that Eneas should be used with caution alongside Non-Steroidal Anti-inflammatory Agents (NSAIDs), which includes common pain relievers like ibuprofen. The cautionary advice is due to the potential for NSAIDs to affect renal function, particularly when combined with an ACE inhibitor component.


Q: Does Eneas cause changes in sleep patterns?

Official adverse reaction lists document insomnia (difficulty falling or staying asleep) as a common side effect. Other changes to sleep patterns are not typically itemized in the summary documentation.


Q: What common foods or drinks are known to interact with Eneas?

The official product information notes that the components of Eneas can interact with grapefruit juice and foods or supplements that are high in potassium. This is based on regulatory guidance for the component drugs.


Q: Does Eneas have a risk of dependence or addiction?

The regulatory risk management plans for the component drugs of Eneas do not list dependence or addiction as an identified or potential risk that requires specific management or monitoring.


Q: What evidence is there about Eneas and long-term use?

Official evidence is primarily established over short-term follow-up durations using blood pressure measurements as the main outcome. Regulatory documents note that there are limited data available from dedicated, long-term Randomized Controlled Trials evaluating the fixed combination's effect on major cardiovascular events.


Q: Is the mechanism of Eneas described as affecting brain chemicals?

The official mechanism of action is described as the two active components primarily acting on the Renin-Angiotensin-Aldosterone System (RAAS) and calcium channels. These systems are responsible for regulating blood pressure in the circulatory system, not brain chemicals.


Q: Why do some people say Eneas gives them an upset stomach?

Official adverse reaction lists document nausea as a very common side effect and diarrhea as a common side effect. These specific reactions are often described by users in everyday language as having an 'upset stomach'.


Q: Is there a generic version of Eneas available?

The active ingredients in Eneas (Enalapril maleate and Nitrendipine) are established medicines and are often available as generic single-agent or combination products. The availability of a generic for the specific brand name 'Eneas' depends on its market status in a given jurisdiction.


Q: What is the risk level for interactions between Eneas and herbal supplements?

General regulatory guidance indicates that herbal remedies and supplements are typically not tested in the same way as prescription medicines for drug interactions. Therefore, there may not be enough information to definitively state that they are safe to take with the components of Eneas.


Q: Is there a known contraindication for Eneas and heart conditions?

Yes, official safety documents list Cardiovascular Shock as an absolute contraindication (must not use). Caution is also officially warranted for patients with certain heart conditions, such as aortic stenosis or severe heart failure, due to their sensitivity to blood pressure effects.


Q: Is Eneas a controlled substance?

Official scheduling from government bodies that regulate drugs confirms that the components of Eneas (Enalapril maleate/Nitrendipine) are not listed as a Schedule I, II, III, IV, or V controlled substance.


Q: Why is it important to share a full medicine list when starting Eneas?

Sharing a full medicine list is necessary because official documents list numerous agents that are contraindicated (must not be combined) or require cautionary monitoring when taken with Eneas. This ensures awareness of potential risks.


Q: Is it true that Eneas is used for more than one condition?

The official label for Eneas fixed-dose combination specifies its common use as the management of essential hypertension (high blood pressure). Any other uses would not be covered in the official summary of indications.


Q: Is Eneas available without a prescription in any country?

Across major international jurisdictions, official labeling classifies Eneas as a prescription-only medicine. This means that it is not available to the public without a prescription from a licensed healthcare professional.


Q: How does the official documentation describe the 'main component' of Eneas?

Official product information describes Eneas as a fixed-dose combination containing Enalapril maleate and Nitrendipine. It does not designate one component as the 'main' one, but rather emphasizes the simultaneous action of the two active ingredients.

How should Eneas be stored and disposed of?

How to Store and Dispose of Eneas

Official storage and disposal requirements for Eneas (enalapril maleate/nitrendipine) tablets are set by regulatory authorities to maintain product stability and ensure safe handling.

Storage Conditions

Eneas must be stored at temperatures below 30 C. To maintain the integrity of the tablets, the medicine must be kept in its original package to protect from light and moisture. Tablets should not be used after the expiry date printed on the packaging.

Safety and Disposal

As a mandatory safety requirement, Eneas must be stored out of the sight and reach of children at all times. Disposal of any unused, expired, or waste material must strictly be carried out in accordance with local regulatory requirements for pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eneas found in:

A-Z Index: